Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Cefaclor→

Cefaclor Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
53994-73-3
Molecular formula
C15H14ClN3O4S
Molecular weight
367.81 g/mol
Drug class
Second-generation oral cephalosporin beta-lactam antibacterial
Mechanism of action
Binds penicillin-binding proteins and inhibits the final transpeptidation step of bacterial peptidoglycan cell-wall synthesis, producing bactericidal activity against susceptible organisms.
Indications / reported uses
  • Treatment of infections caused by cefaclor-susceptible bacteria, including selected otitis media, pharyngitis/tonsillitis, lower respiratory-tract and urinary-tract infections; exact indications depend on the product label and local susceptibility patterns

Sources: US DailyMed — Cefaclor · NLM MeSH — Cefaclor · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Cefaclor Environmental Risk Assessment (ERA) (the Cefaclor ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.